The objectives of this study are to characterise immune responses in people with CoV-SARS-2 infection and use this knowledge to advance vaccine design, treatment options, and diagnostic reagents. Eligible participants will include people diagnosed with SARS-CoV-2 infection, and may include recently returned travellers and non-travellers in the community presenting to tertiary hospital healthcare facilities. Recruitment will be opportunistic, and sampling intensity may vary depending on the phase of the outbreak. Participants can be enrolled at any timepoint (up to 6 months) following diagnosis of SARS-CoV-2 infection (COVID-19). Blood samples and clinical data will be collected.
Study Type
OBSERVATIONAL
Enrollment
200
Plasma and serum will be collected at day 0, day 7, day 14, 1 month and 4 months post diagnosis. Clinical data related to COVID-19 diagnosis, symptoms, and outcomes will be collected.
NSW Health Pathology
Randwick, New South Wales, Australia
RECRUITINGPrince of Wales Hospital
Randwick, New South Wales, Australia
RECRUITINGSydney Children's Hospital
Randwick, New South Wales, Australia
NOT_YET_RECRUITINGBlacktown Hospital
Blacktown, Australia
RECRUITINGRoyal Prince Alfred Hospital
Camperdown, Australia
RECRUITINGSt Vincent's Hospital
Darlinghurst, Australia
RECRUITINGNorthern Beaches Hospital
Frenchs Forest, Australia
RECRUITINGRoyal North Shore Hospital
Saint Leonards, Australia
RECRUITINGWestmead Hospital
Westmead, Australia
RECRUITINGCoronavirus sequencing
The viruses will be sequenced to to help understand epitope specificity
Time frame: 4 months post COVID-19 diagnosis.
Coronavirus culturing
The viruses will then be either cultured to study the immune response against them in culture.
Time frame: 4 months post COVID-19 diagnosis.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.